#COCP

End of 2025 Issue The News GKE Agent Sandbox: At KubeCon NA 2025 we introduced the Agent Sandbox. A new Kubernetes primitive built with the Kubernetes community that’s designed specifically for agent code execution and...

2 months ago

A new edition of #ThisWeekInGKE is out. Check it out 👇

www.linkedin.com/pulse/end-20...

#GoogleCloud #Kubernetes #ThisWeekInGKE #GKE #COCP #GKEAutopilot #TechNews #AI #GenAI

3 0 0 0

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Cocrystal Pharma (Nasdaq: COCP) received Institutional Review Board approval from Emory University School of Medicine to start a Phase 1b human challenge study of CDI-988 for prevention and treatment of norovirus.Key facts: the study follows FDA IND clearance and a Study May Proceed letter, will enroll up to 40 healthy adults (ages 18-49), use norovirus GII.2 challenge, and expects subject enrollment in Q1 2026. Primary endpoint is reduction in clinical symptoms; secondary endpoints include viral shedding and disease severity.

2 months ago

#COCP Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

3 months ago

#COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26… buff.ly/6TyN701

0 0 0 0

4 months ago

#COCP Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules Cocrystal Pharma (Nasdaq: COCP) completed a private placement on October 30, 2025 raising $1.03 million by selling 743,024 common shares at $1.39 per unit and issuing unregistered warrants to buy up to 1,486,048 shares at an exercise price of $1.24. The warrants are exercisable upon issuance and expire in 27 months. Four investors were company insiders and directors, including Phillip Frost, Fred Hassan, Richard Pfenniger and co-CEO/CFO James Martin. If all warrants are exercised for cash, the company would receive approximately $1.83 million more. The company said net proceeds will support clinical development programs, working capital and general corporate purposes. The securities were offered under Section 4(a)(2) and Regulation D and are unregistered.

4 months ago

#COCP Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

5 months ago

🚀 Exciting times for #COCP! With its CDI-988 antiviral drug in the spotlight, this stock is showing potential despite recent pressures. Oversold RSI hints at a rebound opportunity. Consider a cautious long position with targets at $1.30 & $1.40. Stay tuned! 📈 #FeetrAI

0 0 0 0

5 months ago

#COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million… buff.ly/KAuB3O6

0 0 0 0

5 months ago

🚨 FeetrAI Alert: #COCP is in the spotlight! Despite positive news on CDI-988, stock faces pressure from a direct offering. RSI hints at a rebound, but MACD & moving averages show bearish vibes. Consider a SHORT at $1.23, targeting $1.15 & $1.10. Stay cautious! 📉💡 #Stocks #Biotech

0 0 0 0

5 months ago

🚨 Exciting times for #COCP! Despite a dip from a direct offering, their antiviral drug CDI-988 is sparking interest. 📉 Bearish trend with RSI at 41 & MACD showing slight bearish momentum. Short at $1.42? Target $1.35/$1.30, stop loss $1.50. Stay cautious! #FeetrAI

1 0 0 0

6 months ago

🚀 Exciting times for #COCP! With their CDI-988 antiviral drug in the spotlight, a short-term rebound could be on the horizon. Consider a LONG position at $1.38, targeting $1.45 & $1.50. Keep an eye on updates and market sentiment! 📈 #FeetrAI #StockWatch

0 0 0 0

$13 Million Capital Raise: Cocrystal Pharma Secures $4.7M Upfront Plus $8.3M in Warrant Potential Biotech firm Cocrystal Pharma secures $4.7M through registered direct offering at $1.70/share, with additional $8.3M potential from warrants. Closing expected Sept 15, 2025.

6 months ago

#COCP Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

First-Ever Oral Drug for $60B Norovirus Market: Cocrystal's CDI-988 Shows Promise in Phase 1 Safety Study Cocrystal's CDI-988 demonstrates favorable safety profile in Phase 1, targets multiple norovirus strains including GII.4 and GII.17. FDA clears Phase 1b challenge study to begin by year-end.

6 months ago

#COCP Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

6 months ago

New issue of This Week In GKE is out 🙌

www.linkedin.com/posts/sabdel...

#GoogleCloud #Kubernetes #ThisWeekInGKE #GKE #COCP #GKEAutopilot #TechNews #AI #GenAI

1 0 0 0

Container-optimized compute delivers autoscaling for Autopilot | Google Cloud Blog Take a deeper look at autoscaling in GKE Autopilot, and how to start using the new container-optimized compute platform for your workloads today.

6 months ago

It's designed to help you focus on your applications, not your infrastructure. You can learn more about this powerful new feature in the official Google Cloud blog post 👇

cloud.google.com/blog/product...

#GoogleCloud #GKE #Kubernetes #DevOps #CloudComputing #COCP #Autoscaling

2 0 0 0

6 months ago

Google Cloud launched a new autoscaling platform for GKE called Container-Optimized Compute or #COCP

This new feature supercharges your workloads by:
🚀 Reducing pod scheduling delays by up to 7x.
⚙️ Dynamically resizing nodes on the fly.
💰 Optimizing costs by only paying for what you need.

5 0 1 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

6 months ago

#COCP: Norovirus Challenge Study to Initiate in 4Q25… buff.ly/251IV9h

0 0 0 0

Nasdaq

7 months ago

Cocrystal Pharma Narrows Loss in Q2 | The Motley Fool

#COCP #0550eae5-867e-4206-9fc3-a9a4ccc9e341 #data-news

Origin | Interest | Match

0 0 0 0

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Cocrystal Pharma (Nasdaq: COCP) reported Q2 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate CDI-988 showed favorable Phase 1 safety and tolerability results for norovirus treatment. A Phase 1b norovirus challenge study is planned for later in 2025.Financial highlights include Q2 2025 net loss of $2.1 million ($0.20 per share), reduced from $5.3 million in Q2 2024. R&D expenses decreased to $1.1 million from $4.3 million year-over-year. The company reported $4.8 million in cash as of June 30, 2025.CDI-988 demonstrated broad-spectrum activity against norovirus strains, including the prevalent GII.17 strains responsible for 2024-2025 outbreaks. The company's pipeline also includes CC-42344 for influenza treatment, which showed activity against highly pathogenic H5N1 avian influenza strains.

7 months ago

#COCP Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

Military Backs Cocrystal's Breakthrough Norovirus Drug: Phase 1 Shows Perfect Safety Profile All doses of CDI-988 demonstrate strong safety data at military health conference. First-ever oral pan-viral treatment targets both norovirus and coronavirus. See trial results.

7 months ago

#COCP Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

Illustration showing a person clutching their stomach in pain, overlaid with a digital representation of norovirus particles, symbolizing gastrointestinal infection. Image branded with the company name Cocrystal Pharma.

#COCP is gaining attention for its novel antiviral CDI-988, now featured at the upcoming U.S. Department of Defense medical conference. With no approved treatment or vaccine for norovirus, CDI-988 could offer a first-in-class solution.
#CocrystalPharma
prismmarketview.com/cocrystal-ph...

0 0 0 0

Military Defense Selects Revolutionary Norovirus Drug: First-Ever Dual Prevention and Treatment Shows Promise Novel broad-spectrum antiviral shows promise in Phase 1 trials. Military conference to reveal breakthrough data for norovirus prevention and treatment. See results.

9 months ago

#COCP Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain Cocrystal Pharma (NASDAQ: COCP) reports that its investigational drug CC-42344 shows exceptional potency against the 2024 H5N1 avian influenza strain. The drug demonstrated 1,000-fold higher potency compared to Tamiflu, with an EC50 of 0.003 µM versus 2.69 µM for Tamiflu. CC-42344 works by binding to the PB2 protein's conserved active site to inhibit viral replication. This development is particularly significant as the H5N1 virus has recently spread among U.S. dairy cattle, with some human cases reported, raising concerns about potential human-to-human transmission. The CDC's studies indicate extremely low to no population immunity to H5N1 viruses in the U.S., even among those vaccinated for seasonal flu. The company aims to address the multibillion-dollar influenza market, noting that approximately 8% of the U.S. population contracts influenza seasonally, resulting in $11.2 billion in annual direct and indirect costs.

9 months ago

#COCP Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

9 months ago

#COCP: Topline Results for High-Dose Cohort from Phase 1 Trial of CDI-988 Expected in 2Q25… buff.ly/Bu9x55l

0 0 0 0

Breakthrough: Cocrystal's Novel Antiviral CDI-988 Demonstrates Superior Activity Against All Major Norovirus Variants Novel oral pan-viral inhibitor shows promising results against GII.17 and GII.4 strains. Company prepares for US human challenge study. See full clinical data.

10 months ago

#COCP Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity Novel oral antiviral targets emerging GII.17 strains with broad-spectrum activity. First potential treatment for 685M annual cases. See Phase 1 results.

10 months ago

#COCP Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

11 months ago

#COCP: Norovirus Challenge Study Planned for 2025… buff.ly/7T8ViTc

0 0 0 0

Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss Cocrystal advances norovirus and influenza programs while reducing R&D costs. Cash position at $9.9M as company prepares for key clinical trials. Full pipeline analysis inside.

11 months ago

#COCP Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

www.stocktitan.net/news/COCP/cocrystal-phar...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #COCP ) Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

0 0 0 0